Stifel maintains Hold on DXC Technology stock amid unit sale reports

DXC Technology is reportedly in late-stage talks to sell its insurance unit to Eldridge for $2.4 billion, about 10 times EBITDA; the unit generated roughly $1.3 billion in trailing revenue and represented about 14% of adjusted operating income. In fiscal Q1 2027, non-GAAP EPS of $0.40 narrowly missed the $0.41 estimate and revenue of $3.0 billion slightly beat forecasts, while organic revenue fell 6.7% year over year and adjusted EBIT margin contracted to 5.0%. Stifel maintained Hold with a $10.50 target, while TD Cowen raised its target to $12 from $10 and maintained Hold.

Analysis

The sale could make DXC’s equity look optically inexpensive against gross proceeds, but that framing ignores the earnings being sold and the costs that may remain. At the stated 10x EBITDA, the consideration implies about $240 million of unit EBITDA; losing a business that contributes roughly 14% of adjusted operating income could materially dilute the earnings base unless DXC removes overhead or redeploys proceeds at attractive returns. The 10x figure also depends on an assumed D&A allocation, so it is not a clean standalone valuation. Verify taxes, debt and liabilities transferred, stranded costs, and the actual cash available to shareholders or creditors.

Over the next 1–3 months, a signed agreement and explicit proceeds-use plan matter more than press reports or analyst targets. A debt paydown could reduce balance-sheet risk, while buybacks or acquisitions would leave execution risk largely intact. The core business’s organic contraction and margin pressure make a smaller revenue base a potential negative multiple catalyst. Longer term, Eldridge’s ownership of Zinnia could create integration and cross-selling benefits for the buyer, but also raises customer-retention and transition risks for DXC’s remaining business.

The contrarian point: a transaction near the parent’s reported enterprise value is not equivalent to that value accruing to equity, particularly if the company gives up a meaningful earnings contributor. The supplied market capitalization and enterprise-value figures should be reconciled to current filings before drawing valuation conclusions. No direct issuer implication for Stifel Financial or Toronto-Dominion Bank follows from the analyst references.

Key Decisions for Investors

• Do not chase DXC solely on the reported sale price. Treat it as an event-driven watch until a definitive agreement discloses net proceeds, transferred liabilities, taxes, stranded overhead, and the intended use of cash.
• For the next 1–3 months, reassess DXC on transaction terms and subsequent organic-revenue and adjusted-margin guidance. A signed deal plus credible cost removal or debt reduction would improve the thesis; a delay, weak net proceeds, or further core contraction would falsify it.
• If DXC rallies materially on deal headlines before those details are available, consider a cautious short or defined-risk bearish position rather than an outright long; cap exposure because a binding sale and favorable capital allocation could drive a sharp squeeze. No trade is warranted absent a clear catalyst and borrow/options pricing.
• Monitor whether Eldridge/Zinnia integration prompts customer migration, contract changes, or transition costs. Evidence of customer loss or elevated separation costs would increase downside risk; documented retention and cost-removal milestones would reduce it.